

Evolving Paradigms in Hormone Receptor-Positive Breast Cancer

The Rise of Antibody-Drug Conjugates

FRIDAY, 20 OCTOBER 2023 | 10:15–11:45 CEST

SALAMANCA AUDITORIUM, HALL 3, IFEMA MADRID, MADRID, SPAIN

Medscape Oncology

MODERATOR



Javier Cortes, MD, PhD
Head
International Breast Cancer Center, IBCC
Barcelona, Spain

PANELISTS



Sara Hurvitz, MD
Professor of Medicine
Head, Division of Hematology and Oncology
Senior Vice President, Clinical
Research Division
Department of Medicine, UW Medicine
Fred Hutchinson Cancer Center
Seattle, Washington, United States



Peter Fasching, MD
Associate Professor of Gynecology
and Obstetrics Translational Medicine
University Hospital Erlangen
Comprehensive Cancer Center Erlangen-EMN
Erlangen, Germany



Peter Schmid, MD, PhD, FRCP
Lead, Centre for Experimental
Cancer Medicine
Barts Cancer Institute,
St Bartholomew's Hospital
Queen Mary University of London
London, United Kingdom

AGENDA

10:15–10:20

Welcome and Introduction
Javier Cortes, MD, PhD

10:20–10:45

Antibody-Drug Conjugates for HR-Positive Breast Cancer: Where Are We Today?
Peter Fasching, MD

10:45–11:10

Next-Generation Antibody-Drug Conjugates in Practice: A Case-Based Discussion
Sara Hurvitz, MD

11:10–11:30

New Antibody-Drug Conjugates on the Horizon
Peter Schmid, MD, PhD, FRCP

11:30–11:40

Audience Q&A
All Speakers

11:40–11:45

Concluding Remarks
Javier Cortes, MD, PhD